Collaborative Arrangements and Licensing Agreements, Metagenomi License Agreement (Details) - Metagenomi License Agreement [Member] $ in Millions	3 Months Ended
Dec. 31, 2022 USD ($)	Nov. 30, 2022 Target
Collaborative Arrangement and Licensing Agreement [Abstract]
Payment to license intellectual property \| $	$ 80
Research and development expense \| $	$ 80
Maximum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of targets to be researched, developed and commercialized \| Target		4
Number of additional targets to be researched, developed and commercialized \| Target		4

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration